Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Deutetrabenazine). Same strength and form. Confirm the switch with your doctor or pharmacist.
Indications & Uses
Ajuben is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of- Chorea associated with Huntington's disease Tardive dyskinesia in adults.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Patients not presently receiving Tetrabenazine:Chorea associated with Huntington’s disease- Initial dose: 6 mg/day Maintenance dose: 6 mg-48 mg/day Maximum dose: 48 mg/day Tardive dyskinesia- Initial dose: 12 mg/day Maintenance dose: 12 mg-48 mg/day Maximum dose: 48 mg/day Titrate up at weekly intervals by 6 mg per day to a tolerated dose that reduces chorea, up to a maximum recommended daily dosage of 48 mg (24 mg twice daily). Administer total daily dosages of 12 mg or above in two divided doses and administer with foods.Patients receiving Tetrabenazine: If switching patients from tetrabenazine, discontinue tetrabenazine and initiate deutetrabenazine the following day. The recommended initial dosing regimen of deutetrabenazine in patients switching from tetrabenazine to deutetrabenazine is shown in below chert: Current Tetrabenazine daily dosage Initial regimen of Deutetrabenazine 12.5 mg 6 mg once daily 25 mg 6 mg once daily 37.5 mg 9 mg once daily 50 mg 12 mg once daily 62.5 mg 15 mg once daily 75 mg 18 mg once daily 87.5 mg 21 mg once daily 100 mg 24 mg once daily After patients are switched to deutetrabenazine, the dose may be adjusted at weekly intervals.
Side Effects
Most common adverse reactions (>8%) of deutetrabenzine’s are somnolence, diarrhea, dry mouth, and fatigue.
Cautions & Contraindications
Warnings & Precautions
Patients may experience Neuroleptic Malignant Syndrome (discontinue Ajuben if this occurs), Akathisia, agitation, restlessness, and Parkinsonism (reduce the daily dose of Ajuben or discontinue if this occurs) and Sedation/somnolence.
Contraindications
Deutetrabenazine is contraindicated in patients with Suicidal, or untreated/inadequately treated depression, Hepatic impairment and in patients Taking MAOIs, reserpine, or tetrabenazine.